vs
AVANOS MEDICAL, INC.（AVNS）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是AVANOS MEDICAL, INC.的1.1倍（$200.5M vs $180.9M），ROGERS CORP净利率更高（2.2% vs -0.7%，领先3.0%），ROGERS CORP同比增速更快（5.2% vs 0.7%），AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $1.1M），过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs -3.3%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
AVNS vs ROG — 直观对比
营收规模更大
ROG
是对方的1.1倍
$180.9M
营收增速更快
ROG
高出4.5%
0.7%
净利率更高
ROG
高出3.0%
-0.7%
自由现金流更多
AVNS
多$20.2M
$1.1M
两年增速更快
AVNS
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $200.5M |
| 净利润 | $-1.3M | $4.5M |
| 毛利率 | 47.5% | 32.2% |
| 营业利润率 | 1.4% | — |
| 净利率 | -0.7% | 2.2% |
| 营收同比 | 0.7% | 5.2% |
| 净利润同比 | 99.7% | 421.4% |
| 每股收益（稀释后） | $-0.02 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $180.9M | $201.5M | ||
| Q3 25 | $177.8M | $216.0M | ||
| Q2 25 | $175.0M | $202.8M | ||
| Q1 25 | $167.5M | $190.5M | ||
| Q4 24 | $179.6M | $192.2M | ||
| Q3 24 | $170.4M | $210.3M | ||
| Q2 24 | $171.7M | $214.2M |
净利润AVNSROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-1.3M | $4.6M | ||
| Q3 25 | $-1.4M | $8.6M | ||
| Q2 25 | $-76.8M | $-73.6M | ||
| Q1 25 | $6.6M | $-1.4M | ||
| Q4 24 | $-397.3M | $-500.0K | ||
| Q3 24 | $4.3M | $10.7M | ||
| Q2 24 | $1.8M | $8.1M |
毛利率AVNSROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 47.5% | 31.5% | ||
| Q3 25 | 48.4% | 33.5% | ||
| Q2 25 | 52.6% | 31.6% | ||
| Q1 25 | 53.6% | 29.9% | ||
| Q4 24 | 54.6% | 32.1% | ||
| Q3 24 | 54.5% | 35.2% | ||
| Q2 24 | 55.7% | 34.1% |
营业利润率AVNSROG
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 3.5% | ||
| Q3 25 | 0.1% | 7.3% | ||
| Q2 25 | -42.6% | -33.3% | ||
| Q1 25 | 6.1% | -0.2% | ||
| Q4 24 | -233.0% | -6.6% | ||
| Q3 24 | 7.0% | 6.9% | ||
| Q2 24 | 3.7% | 5.3% |
净利率AVNSROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | -0.7% | 2.3% | ||
| Q3 25 | -0.8% | 4.0% | ||
| Q2 25 | -43.9% | -36.3% | ||
| Q1 25 | 3.9% | -0.7% | ||
| Q4 24 | -221.2% | -0.3% | ||
| Q3 24 | 2.5% | 5.1% | ||
| Q2 24 | 1.0% | 3.8% |
每股收益（稀释后）AVNSROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.02 | $0.20 | ||
| Q3 25 | $-0.03 | $0.48 | ||
| Q2 25 | $-1.66 | $-4.00 | ||
| Q1 25 | $0.14 | $-0.08 | ||
| Q4 24 | $-8.64 | $-0.04 | ||
| Q3 24 | $0.09 | $0.58 | ||
| Q2 24 | $0.04 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $195.8M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $1.2B |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $89.8M | $197.0M | ||
| Q3 25 | $70.5M | $167.8M | ||
| Q2 25 | $90.3M | $157.2M | ||
| Q1 25 | $97.0M | $175.6M | ||
| Q4 24 | $107.7M | $159.8M | ||
| Q3 24 | $89.0M | $146.4M | ||
| Q2 24 | $92.2M | $119.9M |
总债务AVNSROG
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
股东权益AVNSROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $778.2M | $1.2B | ||
| Q3 25 | $778.0M | $1.2B | ||
| Q2 25 | $776.3M | $1.2B | ||
| Q1 25 | $839.4M | $1.3B | ||
| Q4 24 | $828.5M | $1.3B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B |
总资产AVNSROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.5B |
负债/权益比AVNSROG
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $1.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 0.5% |
| 资本支出强度资本支出/营收 | 3.8% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $70.1M |
8季度趋势，按日历期对齐
经营现金流AVNSROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $28.2M | $46.9M | ||
| Q3 25 | $14.0M | $28.9M | ||
| Q2 25 | $6.8M | $13.7M | ||
| Q1 25 | $25.7M | $11.7M | ||
| Q4 24 | $57.9M | $33.7M | ||
| Q3 24 | $23.0M | $42.4M | ||
| Q2 24 | $27.8M | $22.9M |
自由现金流AVNSROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $21.3M | $42.2M | ||
| Q3 25 | $7.0M | $21.2M | ||
| Q2 25 | $-4.2M | $5.6M | ||
| Q1 25 | $19.0M | $2.1M | ||
| Q4 24 | $53.1M | $18.3M | ||
| Q3 24 | $20.0M | $25.2M | ||
| Q2 24 | $21.9M | $8.8M |
自由现金流率AVNSROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 11.8% | 20.9% | ||
| Q3 25 | 3.9% | 9.8% | ||
| Q2 25 | -2.4% | 2.8% | ||
| Q1 25 | 11.3% | 1.1% | ||
| Q4 24 | 29.6% | 9.5% | ||
| Q3 24 | 11.7% | 12.0% | ||
| Q2 24 | 12.8% | 4.1% |
资本支出强度AVNSROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 3.8% | 2.3% | ||
| Q3 25 | 3.9% | 3.6% | ||
| Q2 25 | 6.3% | 4.0% | ||
| Q1 25 | 4.0% | 5.0% | ||
| Q4 24 | 2.7% | 8.0% | ||
| Q3 24 | 1.8% | 8.2% | ||
| Q2 24 | 3.4% | 6.6% |
现金转化率AVNSROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 3.96× | ||
| Q2 24 | 15.44× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ROG
暂无分部数据
